Albuquerque, NM, July 28, 2026 – Indica Labs, the world’s leading provider of AI-powered digital pathology solutions, today announced new intelligent tissue classification capabilities for HALO Breast IHC AI, its AI-powered breast biomarker quantification suite, seamlessly deployed in HALO AP®. This enhanced new version introduces fully automated identification and exclusion of positive control tissue, ductal carcinoma in situ (DCIS), lobular carcinoma in situ (LCIS), and areas of benign tissue prior to biomarker analysis. This zero-click preprocessing and tissue classification workflow represents a critical step in ensuring accurate and reproducible AI outputs.

Accurate breast cancer biomarker assessment depends not only on how biomarkers are quantified, but also on which tissue is analyzed. Biomarker expression within the invasive tumor component is an established part of invasive breast cancer evaluation. However, whole-slide images frequently contain additional tissue architecture including DCIS, LCIS, benign structures, and control tissue, that can demonstrate heterogeneous biomarker staining patterns. If inadvertently included in quantitative analysis of invasive tumors, these regions may influence biomarker measurements and increase variability between observers.

“Reliable AI-powered biomarker quantification begins with analyzing the correct tissue,” said, Dr. Peter Caie, Senior Director of Precision Medicine at Indica Labs. “With the addition of pre-analytical, automated tissue classification, we have turned our HALO Breast IHC AI suite from just another scoring algorithm into computational pathology intelligence, determining what should be measured before a fully automated quantitation is performed, mirroring the steps an expert pathologist would take.”

By performing intelligent tissue selection before biomarker quantification, this algorithm reduces time-consuming manual region selection. This helps laboratories reduce variability introduced by manual annotations, improve reproducibility, and minimize preprocessing time for routine breast biomarker workflows. HALO Breast IHC AI advancements improve confidence that biomarker scoring accurately reflects the invasive tumor component intended for evaluation.  

For more information about HALO Breast IHC AI, HALO Clinical AI Solutions, and how these algorithms can enhance efficiency and accuracy in your laboratory, contact info@indicalab.com.

Regulatory

HALO Breast IHC AI is For Research Use Only and not intended for clinical diagnostic use. HALO Breast IHC AI is accessed via the HALO AP® enterprise digital pathology platform.

HALO AP® is CE-IVDR marked for in-vitro diagnostic use in Europe, the UK, and Switzerland. HALO AP® is For Research Use Only in the USA and is not FDA cleared for clinical diagnostic use. In addition, HALO AP® provides built-in compliance with FDA 21 CFR Part 11, HIPAA, and GDPR. PRR-MAR-000012v1

About Indica Labs:

Indica Labs, the global leader in AI-powered digital pathology, is redefining medicine with pathology platforms supporting life science discovery, translational research, clinical workflows, and companion diagnostic development. HALO platforms integrate image management and quantitative image analysis to deliver standardized, reproducible tissue-based analysis at every stage of the translational journey.

Media Contact:

Jenna Karpel    

jkarpel@indicalab.com